Institute of Cardiovascular and Medical Sciences, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Western Infirmary, Glasgow G11 6NT, UK.
Br J Clin Pharmacol. 2012 Feb;73(2):187-93. doi: 10.1111/j.1365-2125.2011.04092.x.
People with pre-hypertension (high blood pressure but below the conventional threshold for intervention with antihypertensive drugs) undoubtedly have increased risk of cardiovascular and other complications. However, the vast majority has low absolute risk and whether treatment would be beneficial is uncertain. While pharmacotherapy has attractions from a public health perspective, clinicians and crucially those with pre-hypertension require robust evidence that drug treatment will lead to short term as well as long term gains. Any changes in recommendations should await adequately powered outcome studies which provide solid evidence of the magnitude of absolute risk reduction in treating pre-hypertension and assessment of the cost-effectiveness.
患有前期高血压(血压升高但尚未达到采用抗高血压药物进行干预的传统标准)的人无疑具有增加心血管和其他并发症的风险。然而,绝大多数人具有较低的绝对风险,且治疗是否有益尚不确定。虽然从公共卫生角度来看,药物治疗具有吸引力,但临床医生,尤其是前期高血压患者,需要有强有力的证据表明药物治疗将带来短期和长期收益。任何推荐的改变都应等待有足够效力的结果研究提供治疗前期高血压的绝对风险降低幅度的可靠证据,并评估成本效益。